Drug General Information
Drug ID	D0F3NH
Former ID	DIB012779
Drug Name	Balaglitazone
Synonyms	DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645
Drug Type	Small molecular drug
Indication	Type 1 diabetes [ICD9: 250; ICD10:E10]		Phase 3	[522085]
Company	Dr Reddy's Research Foundation
Structure		Download 2D MOL 3D MOL
Formula	C20H17N3O4S
Canonical SMILES	n1(c(=O)c2c(nc1COc1ccc(CC3C(=O)NC(=O)S3)cc1)cccc2)C
CAS Number	CAS 199113-98-9
PubChem Compound ID	9889200
Target and Pathway
Target(s)	Peroxisome proliferator activated receptor gamma	Target Info	Modulator
KEGG Pathway	PPAR signaling pathway
	AMPK signaling pathway
	Osteoclast differentiation
	Huntington's disease
	Pathways in cancer
	Transcriptional misregulation in cancer
	Thyroid cancer
NetPath Pathway	IL1 Signaling Pathway
	TGF_beta_Receptor Signaling Pathway
	Leptin Signaling Pathway
PANTHER Pathway	CCKR signaling map ST
Pathway Interaction Database	Noncanonical Wnt signaling pathway
	Calcineurin-regulated NFAT-dependent transcription in lymphocytes
	Signaling events mediated by HDAC Class I
	RXR and RAR heterodimerization with other nuclear receptor
	Regulation of retinoblastoma protein
Reactome	PPARA activates gene expression
	Transcriptional regulation of white adipocyte differentiation
	Nuclear Receptor transcription pathway
WikiPathways	Wnt Signaling Pathway Netpath
	Nuclear Receptors in Lipid Metabolism and Toxicity
	Differentiation of white and brown adipocyte
	Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
	Transcriptional Regulation of White Adipocyte Differentiation
	Adipogenesis
	SREBP signalling
	Nuclear Receptors
References
Ref 522085	ClinicalTrials.gov (NCT00515632) Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.